Carla Nester, MD, MSA, FASN
Carla M. Nester, MD, MSA, FASN, is the Jean Robillard MD Professor of Pediatrics, and the Division Director of Pediatric Nephrology at the University of Iowa, Stead Family Children's Hospital in Iowa City, IA. In addition, she is the Associate Director of the Molecular Otolaryngology and Renal Research Laboratory (MORL), one of the largest combined clinical, genetic and research laboratories in North America with a focus on complement biology in kidney disease.
Dr Nester is an Internal Medicine and Pediatric trained (quadruple boarded) NIH-funded, tenured faculty member with a translational research program focusing on rare complement-mediated kidney disease - including aHUS and C3G. She is the primary investigator for the University of Iowa’s C3 Glomerulopathy Natural History Study, which includes one of the largest prospective cohorts of patients with C3 Glomerulopathy available to research. Finally, Dr Nester is a clinical trialist. Her Internal Medicine and Pediatric clinical practice has become a hub for bringing the new generation of anticomplement therapeutics to a rare disease population.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovartisTopic:C3 GlomerulopathyDate added:01/26/2024Date updated:01/29/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ApellisTopic:C3 GlomerulopathyDate added:01/26/2024Date updated:01/29/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:KiraTopic:C3 GlomerulopathyDate added:01/26/2024Date updated:01/29/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AchillionTopic:C3 GlomerulopathyDate added:01/26/2024Date updated:01/29/2024Relationship end date:08/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BiocrystTopic:C3 GlomerulopathyDate added:01/26/2024Date updated:01/29/2024Relationship end date:01/01/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ChemoCentryxTopic:ANCADate added:01/29/2024Date updated:01/29/2024Relationship end date:03/15/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:RetrophinTopic:FSGSDate added:01/29/2024Date updated:01/29/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Silence TherapeuticsTopic:PNHDate added:01/29/2024Date updated:01/29/2024Relationship end date:08/08/2023